Actinium Stock Discussion

$Actinium(ATNM.US)$ gem

$Actinium(ATNM.US)$ Reuters· 2 mins ago
Actinium Pharmaceuticals Inc- Iomab-B Achieved Primary Endpoint of Durable Complete Remission (Dcr) With High Statistical Significance (P<0.0001)

$Actinium(ATNM.US)$ Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial
- Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did no...

$Actinium(ATNM.US)$
NEWS
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial
Actinium Pharmaceuticals announced that the Phase 3 SIERRA trial results of Iomab-B will be presented at the EHA 2024 Congress. The trial demonstrated significant survival benefits in older patients wit...

$Actinium(ATNM.US)$
NEWS
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting

$Actinium(ATNM.US)$ Actinium Pharmaceuticals Granted U.S. Patent #11844799: Method for Treating Cancer Using a BCL-2 Inhibitor in Conjunction With an Alpha-emitting Radioimmunotherapeutic

$Actinium(ATNM.US)$ Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition
PR Newswire· 1 min ago

$Actinium(ATNM.US)$ Ionetix to provide Bayer with Therapeutic Radioisotope Actinium-225 (Ac-225)
3 MINUTES AGO, 6:00 AM EST
VIA PR NEWSWIRESHARE
LANSING, Mich., Nov. 15, 2023 /PRNewswire/ -- Ionetix Corporation today announced the signing of a supply agreement for the therapeutic radioisotope actinium-225 (Ac-225) with Bayer. Under the terms of the agreement, Ionetix will provide Bayer with high-purity, non-carrier added (n.c.a.) Ac-225.

$Actinium(ATNM.US)$ Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy